glp-1 agonists cardiovascular diseases disease continuum-GLP-1 action. Adapted from [46] GLP-1 receptor agonists improve cardiovascular

Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

Some research suggests adding semaglutide (the active ingredient in Wegovy) to metformin may help improve blood sugar control and lead to more weight loss than metformin alone

Abbreviations: GIP, glucosedependent insulinotropic polypeptide

doi: 10.1016/j.cct.2023.107176 [DOI] [PubMed] [Google Scholar] 204.Sanyal AJ, Bedossa P, Fraessdorf M, et al

Proven Weight Loss: Clinical studies, including the SURMOUNT-1 trial, have shown that Mounjaro can help people with obesity (without diabetes) lose an average of 15% to over 20% of their body weight